Nothing Special   »   [go: up one dir, main page]

AR064444A1 - Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas - Google Patents

Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas

Info

Publication number
AR064444A1
AR064444A1 ARP070105721A ARP070105721A AR064444A1 AR 064444 A1 AR064444 A1 AR 064444A1 AR P070105721 A ARP070105721 A AR P070105721A AR P070105721 A ARP070105721 A AR P070105721A AR 064444 A1 AR064444 A1 AR 064444A1
Authority
AR
Argentina
Prior art keywords
halogen atoms
groups
group
substituents selected
optionally substituted
Prior art date
Application number
ARP070105721A
Other languages
English (en)
Inventor
Palomino Laria Julio Cesar Castro
Sola Montserrat Erra
Toribio Maria Estrella Lozoya
Romero Eloisa Navarro
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200701086A external-priority patent/ES2327372B1/es
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of AR064444A1 publication Critical patent/AR064444A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Composiciones farmacéuticas. Reivindicacion 1: Un compuesto de formula (1) en donde: uno de los grupos G1 representa un átomo de nitrogeno o un grupo CRc y el otro representa un grupo CRc; G2 representa un átomo de nitrogeno o un grupo CRd; R1 representa un grupo seleccionado de átomos de hidrogeno, átomos de halogeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, y grupos cicloalquilo C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi; R2 representa un grupo seleccionado de átomos de hidrogeno, átomos de halogeno, grupos hidroxilo, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, y grupos cicloalquilo C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi; Ra, Rb y Rc representan independientemente grupos seleccionado de átomos de hidrogeno, átomos de halogeno, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi; Rd representa un grupo seleccionado de átomos de hidrogeno, átomos de halogeno, grupos hidroxilo, grupos alquilo C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, y grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, y grupos cicloalcoxi C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi; uno de los grupos G3 y G4 es un átomo de nitrogeno y el otro es un grupo CH, M es un átomo de hidrogeno o un cation farmacéuticamente aceptable, con la condicion de que, cuando al menos uno de los grupos Ra y Rb representa un átomo de hidrogeno y G2 es un grupo CRd, entonces Rd representa un grupo seleccionado de grupos alcoxi C1-4 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi, grupos cicloalcoxi C3-8 que pueden estar opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de átomos de halogeno y grupo hidroxi; y sus sales y N-oxidos farmacéuticamente aceptables.
ARP070105721A 2006-12-22 2007-12-19 Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas AR064444A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200603250A ES2319596B1 (es) 2006-12-22 2006-12-22 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES200701086A ES2327372B1 (es) 2007-04-23 2007-04-23 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.

Publications (1)

Publication Number Publication Date
AR064444A1 true AR064444A1 (es) 2009-04-01

Family

ID=39319647

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105721A AR064444A1 (es) 2006-12-22 2007-12-19 Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas

Country Status (32)

Country Link
US (2) US8258308B2 (es)
EP (1) EP2121614B1 (es)
JP (1) JP5318776B2 (es)
KR (1) KR101435233B1 (es)
CN (1) CN101589025B (es)
AR (1) AR064444A1 (es)
AU (1) AU2007338321B2 (es)
BR (1) BRPI0717697B1 (es)
CA (1) CA2674512C (es)
CL (1) CL2007003666A1 (es)
CY (1) CY1113687T1 (es)
DK (1) DK2121614T3 (es)
EC (1) ECSP099395A (es)
ES (2) ES2319596B1 (es)
HK (1) HK1133014A1 (es)
HR (1) HRP20120697T1 (es)
IL (1) IL199188A (es)
ME (1) ME01475B (es)
MX (1) MX2009006408A (es)
MY (1) MY153393A (es)
NO (1) NO341991B1 (es)
NZ (1) NZ577017A (es)
PE (1) PE20081846A1 (es)
PL (1) PL2121614T3 (es)
PT (1) PT2121614E (es)
RS (1) RS52514B (es)
RU (1) RU2469024C2 (es)
SI (1) SI2121614T1 (es)
TW (1) TWI405572B (es)
UY (1) UY30794A1 (es)
WO (1) WO2008077639A1 (es)
ZA (1) ZA200903335B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007247190A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2327372B1 (es) * 2007-04-23 2010-08-24 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011004870A (es) * 2008-11-07 2011-09-06 4Sc Ag Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) * 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
EP2444088A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
US10016402B2 (en) 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en) 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
US9624215B2 (en) * 2012-10-31 2017-04-18 Toyama Chemical Co., Ltd. Amine derivative or salt thereof
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
AU2014352920A1 (en) 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
AU2014390300A1 (en) 2014-04-11 2016-10-20 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
ES2960598T3 (es) * 2014-05-08 2024-03-05 Kiora Pharmaceuticals Gmbh Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
WO2016200778A1 (en) * 2015-06-08 2016-12-15 Children's Medical Center Corporation Methods for treatment of melanoma
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
EP3590920A4 (en) * 2017-03-02 2021-01-06 Shanghai Institute of Materia Medica, Chinese Academy of Sciences AROMATIC FORMIATE 2-FTO INHIBITOR (SUBSTITUTED BENZENE MATRIX), PROCESS OF PREPARATION AND APPLICATIONS
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
JP6978251B2 (ja) * 2017-03-03 2021-12-08 アスラン ファーマシューティカルズ ピーティーイー リミテッド がん治療
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
US20220364065A1 (en) 2018-12-21 2022-11-17 National University Corporation Hokkaido University Composition for removing pluripotent stem cells and method of removing pluripotent stem cells
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
EP4052760B1 (en) * 2019-10-31 2024-03-13 FUJIFILM Corporation Pyrazine derivative or salt thereof, and use of same
CN116056766A (zh) * 2020-07-30 2023-05-02 富士胶片株式会社 含氮杂环化合物或其盐、其利用以及其中间体
EP4228640A1 (en) * 2020-10-15 2023-08-23 ASLAN Pharmaceuticals Pte Ltd Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
WO2023147161A2 (en) * 2022-01-31 2023-08-03 New Frontier Bio, Inc. Nicotinate and nicotinamide riboside-based compounds and derivatives thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529490A (en) * 1894-11-20 hegg-em
EP0040896B1 (en) * 1978-08-22 1984-04-25 Sumitomo Chemical Company, Limited Synthesis of amides
JPH05331163A (ja) * 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
EP0672041B1 (en) * 1993-10-01 2001-11-14 Novartis AG Pharmacologically active pyridine derivatives and processes for the preparation thereof
IL122494A (en) 1995-06-21 2001-08-08 Asta Medica Ag A cartridge for pharmaceutical powder with a measuring device and an integral inhaler for powdered medicines
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
YU86701A (sh) * 1999-06-10 2004-09-03 Warner-Lambert Company Jedinjenja i formulacije za inhibiciju agregacije proteina i snimanje amiloidnih naslaga
ATE396719T1 (de) 2001-04-05 2008-06-15 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
PE20030120A1 (es) 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) * 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
MXPA06013435A (es) 2004-05-21 2007-03-23 Uab Research Foundation Composiciones y metodos referentes a inhibidores de sintesis de pirimidina.
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
MX2007004265A (es) 2004-10-19 2008-03-04 Aventis Pharma Inc Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino.
CA2582247C (en) * 2004-10-20 2014-02-11 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
CA2677457A1 (en) 2007-02-06 2008-08-14 Helen Tuvesson Andersson New compounds, methods for their preparation and use thereof
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
EP2121614A1 (en) 2009-11-25
ME01475B (me) 2014-04-20
PE20081846A1 (es) 2008-12-27
NO20092380L (no) 2009-07-14
US8691852B2 (en) 2014-04-08
BRPI0717697A2 (pt) 2016-03-22
WO2008077639A1 (en) 2008-07-03
BRPI0717697B1 (pt) 2022-05-03
HRP20120697T1 (hr) 2012-09-30
CL2007003666A1 (es) 2008-07-04
CN101589025A (zh) 2009-11-25
US20120294854A1 (en) 2012-11-22
ECSP099395A (es) 2009-07-31
DK2121614T3 (da) 2012-09-17
KR20090090352A (ko) 2009-08-25
MY153393A (en) 2015-02-13
IL199188A (en) 2014-06-30
RS52514B (en) 2013-04-30
CY1113687T1 (el) 2016-06-22
JP5318776B2 (ja) 2013-10-16
MX2009006408A (es) 2009-06-23
ZA200903335B (en) 2010-06-30
NO341991B1 (no) 2018-03-12
US20100074898A1 (en) 2010-03-25
AU2007338321B2 (en) 2012-01-19
HK1133014A1 (en) 2010-03-12
PT2121614E (pt) 2012-08-31
RU2469024C2 (ru) 2012-12-10
RU2009127847A (ru) 2011-01-27
PL2121614T3 (pl) 2012-11-30
JP2010513362A (ja) 2010-04-30
ES2319596A1 (es) 2009-05-08
KR101435233B1 (ko) 2014-08-28
EP2121614B1 (en) 2012-06-20
CA2674512A1 (en) 2008-07-03
CA2674512C (en) 2015-09-08
US8258308B2 (en) 2012-09-04
SI2121614T1 (sl) 2012-10-30
TW200833332A (en) 2008-08-16
ES2389785T3 (es) 2012-10-31
AU2007338321A1 (en) 2008-07-03
TWI405572B (zh) 2013-08-21
NZ577017A (en) 2011-12-22
ES2319596B1 (es) 2010-02-08
CN101589025B (zh) 2012-05-30
UY30794A1 (es) 2008-05-31

Similar Documents

Publication Publication Date Title
AR064444A1 (es) Derivados de los acidos amino- nicotinico y amino-isonicotinico. composiciones farmaceuticas
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CO6300864A2 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR070993A1 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales como
AR060525A1 (es) Piridin [3,4-b] pirazinonas. composiciones farmaceuticas
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
CO5720994A2 (es) Derivados sustituidos del pirrol
NI200600279A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica
AR053453A1 (es) Derivados de aminoalquil- y amidoalquil-benzopirano substituidos
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
AR062294A1 (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
CO6251285A2 (es) Derivado de tetrahidroisoquinolina novedoso
HN2009000504A (es) Derivados de pirrolizina, indolizina y quinolizina su preparacion y su aplicacion en terapeutica.
AR057615A1 (es) Derivados de isoquinolina y benzo (h) isoquinolina su preparcion y su utilizacion en terapeutica
AR069700A1 (es) Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.

Legal Events

Date Code Title Description
FG Grant, registration